See today's BioWorld Asia
To read the full story, subscribe or sign in.

Takeda bolsters oncology pipeline via $1.3B deal for Keros’ elritercept

Dec. 10, 2024
By Tamra Sami
Takeda Pharmaceutical Co. Ltd. is licensing Keros Therapeutics Inc.’s activin inhibitor elritercept in a global development and commercialization deal worth up to $1.3 billion that excludes mainland China, Hong Kong and Macau.
BioWorld Asia Deals and M&A Cancer Hematologic Protein Asia-Pacific Japan